Additional clinical outcomes
At a median follow-up of 37 months (range 11 to 69 months), eight
patients had died due to disease progression or complications
(Table 3 ). The median overall survival following TPO-RA
initiation was 15 months (range: 1-48 months). Five patients relapsed
following TPO-RA initiation: three patients with pre-B-ALL, one patient
with myelodysplastic syndrome (MDS) that transformed to acute myeloid
leukemia (AML) prior to TPO-RA initiation, and one patient with
B/Myeloid mixed phenotypic acute leukemia (MPAL). The median
relapse-free survival was 6 months (range: 0-46 months). No patients
developed a new myeloid malignancy.